The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Alshareef, Abdulraheem ^a,b   Zhang, Hai Feng ^a,c   Huang, Yung Hsing ^a   Wu, Chengsheng ^a   Zhang, Jing Dong ^d   Wang, Peng ^a   El Sehemy, Ahmed ^e   Fares, Mohamed ^f   Lai, Raymond ^a,g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b TAIBAH UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CHINA MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF TORONTO   (Canada)

^f NATIONAL RESEARCH CENTRE   (Egypt)

^g DynaLIFE Dx   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BETA CATENIN; CRIZOTINIB; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SMALL INTERFERING RNA;

APOPTOSIS; CHEMISTRY; CONFORMATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; HUMAN; IC50; METABOLISM; MOLECULAR MODEL; MUTATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84988492916     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33710     Document Type: Article

References (63)

1. Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994).
2. Shiota, M. et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9, 1567-1574 (1994).
3. Hallberg, B. & Palmer, R. H. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 13, 685-700 (2013).
4. Grande, E., Bolos, M. V. & Arriola, E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 10, 569-579 (2011).
5. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
6. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
7. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
8. George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
9. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
10. Mosse, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
11. Caren, H., Abel, F., Kogner, P. & Martinsson, T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. The Biochemical journal 416, 153-159 (2008).
12. Bresler, S. C. et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 26, 682-694 (2014).
13. Barreca, A. et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 47, R11-R23 (2011).
14. Mosse, Y. P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The Lancet. Oncology 14, 472-480 (2013).
15. Gambacorti-Passerini, C., Messa, C. & Pogliani, E. M. Crizotinib in Anaplastic Large-Cell Lymphoma. New England Journal of Medicine 364, 775-776 (2011).
16. Perez, C. A., Velez, M., Raez, L. E. & Santos, E. S. Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. Lung Cancer 84, 110-115 (2014).
17. Voena, C. & Chiarle, R. The battle against ALK resistance: successes and setbacks. Expert opinion on investigational drugs 21, 1751-1754 (2012).
18. Katayama, R. et al. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Science Translational Medicine 4, 120ra117-120ra117 (2012).
19. Heuckmann, J. M. et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 4682-4690 (2012).
20. Lei, Y.-Y. et al. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. Journal of Thoracic Disease 7, 1181-1188 (2015).
21. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
22. Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nature protocols 9, 2100-2122 (2014).
23. Jensen, A. J., Martinez Molina, D. & Lundback, T. CETSA: a target engagement assay with potential to transform drug discovery. Future medicinal chemistry 7, 975-978 (2015).
24. Boutterin, M. C. et al. Control of ALK (wild type and mutated forms) phosphorylation: Specific role of the phosphatase PTP1B. Cellular Signalling 25, 1505-1513 (2013).
25. Martelli, M. P. et al. EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues. The American Journal of Pathology 174, 661-670 (2009).
26. Ceccon, M., Mologni, L., Bisson, W., Scapozza, L. & Gambacorti-Passerini, C. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Molecular cancer research: MCR 11, 122-132 (2013).
27. Christensen, J. G. et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6, 3314-3322 (2007).
28. Peron, M., Lovisa, F., Poli, E., Basso, G. & Bonvini, P. Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors. PLoS One 10, e0132330 (2015).
29. Robertson, F. et al. Presence of anaplastic lymphoma kinase in inflammatory breast cancer. SpringerPlus 2, 497 (2013).
30. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-307 (2012).
31. Lai, R. & Ingham, R. J. The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update. Ther Adv Hematol 4, 119-131 (2013).
32. Anand, M., Lai, R. & Gelebart, P. beta-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica 96, 253-261 (2011).
33. Hegazy, S. A. et al. Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma. Cell Signal 25, 295-307 (2013).
34. + Lymphoma Cells by the Hsp90 Antagonist 17-Allylamino,17-demethoxygeldanamycin. Cancer Research 62, 1559-1566 (2002).
35. Sang, J. et al. Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Cancer Discovery 3, 430-443 (2013).
36. Katayama, R. et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proceedings of the National Academy of Sciences 108, 7535-7540 (2011).
37. Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Journal of medicinal chemistry 54, 6342-6363 (2011).
38. Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. The New England journal of medicine 363, 1734-1739 (2010).
39. Martinsson, T. et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res 71, 98-105 (2011).
40. Doebele, R. C. et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clinical Cancer Research 18, 1472-1482 (2012).
41. Katayama, R. et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 5686-5696 (2014).
42. Sakamoto, H. et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19, 679-690 (2011).
43. Kodama, T., Tsukaguchi, T., Yoshida, M., Kondoh, O. & Sakamoto, H. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer letters 351, 215-221 (2014).
44. Bresler, S. C. et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Science translational medicine 3, 108ra114 (2011).
45. Zdzalik, D. et al. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPMALK-positive anaplastic large-cell lymphoma. Journal of Cancer Research and Clinical Oncology 140, 589-598 (2014).
46. Ceccon, M., Mologni, L., Bisson, W., Scapozza, L. & Gambacorti-Passerini, C. Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors. Molecular Cancer Research 11, 122-132 (2013).
47. Moore, N. F. et al. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALKmutated neuroblastoma. Oncotarget 5, 8737-8749 (2014).
48. Coluccia, A. M. L. et al. Bcr-Abl stabilizes β -catenin in chronic myeloid leukemia through its tyrosine phosphorylation. The EMBO Journal 26, 1456-1466 (2007).
49. Heidel, F. H. et al. Genetic and Pharmacologic Inhibition of β -Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML. Cell Stem Cell 10, 412-424 (2012).
50. Hoschuetzky, H., Aberle, H. & Kemler, R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. The Journal of Cell Biology 127, 1375-1380 (1994).
51. Lee, C.-H., Hung, H.-W., Hung, P.-H. & Shieh, Y.-S. Epidermal growth factor receptor regulates β -catenin location, stability, and transcriptional activity in oral cancer. Molecular Cancer 9, 1-12 (2010).
52. Togashi, Y. et al. Inhibition of beta-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-smallcell lung cancer with a T790M mutation. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10, 93-101 (2015).
53. Huber, K. V. et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508, 222-227 (2014).
54. Tan, B. X. et al. Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays. Scientific reports 5, 12116 (2015).
55. Na, Z. et al. A small-molecule protein-protein interaction inhibitor of PARP1 that targets its BRCT domain. Angewandte Chemie (International ed. in English) 54, 2515-2519 (2015).
56. Bai, L. et al. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One 9, e99404 (2014).
57. Xu, T. Y. et al. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase. Scientific reports 5, 10043 (2015).
58. Chan-Penebre, E. et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nature chemical biology 11, 432-437 (2015).
59. Griffin, C. A. et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 59, 2776-2780 (1999).
60. Amin, H. M. et al. Characterization of 4 mantle cell lymphoma cell lines. Archives of pathology & laboratory medicine 127, 424-431 (2003).
61. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
62. Narayanan, R. et al. Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation. PLoS One 8, e83380 (2013).
63. Wu, F., Wang, P., Young, L. C., Lai, R. & Li, L. Proteome-Wide Identification of Novel Binding Partners to the Oncogenic Fusion Gene Protein, NPM-ALK, using Tandem Affinity Purification and Mass Spectrometry. The American Journal of Pathology 174, 361-370 (2009).